Saturday, November 29, 2014 Last update: Yesterday, 7:03 PM
FreshNews.com - Covering Large & Obscure Tech Companies Since 1996

Cumberland Pharmaceuticals To Announce Second Quarter 2014 Financial Results On August 5, 2014

Companies mentioned in this article: Cumberland Pharmaceuticals Inc.

NASHVILLE, Tenn., July 22, 2014 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced today that it will release second quarter 2014 financial results after the market closes on Tuesday, August 5, 2014. A conference call and live Internet webcast will be held on Tuesday, August 5, 2014, at 4:30 p.m. Eastern Time to discuss the results.

http://photos.prnewswire.com/prnvar/20140505/84325

To participate in the call, please dial 877-303-1298 (for U.S. callers) or 253-237-1032 (for international callers). A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 855-859-2056 (for U.S. callers) or 404-537-3406 (for international callers). The Conference ID for the rebroadcast is 77335881. The live webcast and rebroadcast can be accessed via Cumberland's website at http://investor.shareholder.com/cpix/events.cfm.

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland's marketed products include Acetadote(®) (acetylcysteine) Injection for the treatment of acetaminophen poisoning, Caldolor(®) (ibuprofen) Injection, for treatment of pain and fever, Kristalose(®) (lactulose) for Oral Solution, a prescription laxative, Vaprisol(® )(conivaptan) Injection, for the treatment of hyponatremia and Omeclamox-Pak(®) for the treatment of H. pylori and duodenal ulcer disease. Cumberland is dedicated to providing innovative products that improve quality of care for patients. For more information on Cumberland, please visit the Company's website www.cumberlandpharma.com.

Logo - http://photos.prnewswire.com/prnh/20140505/84325

SOURCE Cumberland Pharmaceuticals Inc.